“`html
Nerve Blocks Offer New Hope for Migraine Sufferers, Prompting Guideline Updates
Table of Contents
A importent shift in migraine treatment is underway, with researchers recommending occipital nerve blocks as a first-line therapy for acute attacks in emergency departments. The updated guidelines, published in Headache: The Journal of Head and Face Pain, aim to improve patient outcomes and reduce reliance on opioid medications.
A patient who recently received the treatment described the relief as transformative, stating, “For the first time, I am not screaming in agony.” This sentiment underscores the potential impact of the new recommendations for the millions who suffer from debilitating migraines.
A Neurologist’s Personal Journey to breakthrough Research
Dr. Serena Orr, a neurologist and researcher at the University of Calgary’s Cumming School of Medicine, spearheaded the research. Her dedication to finding effective migraine treatments was unexpectedly deepened by her own experience with a severe attack during the COVID-19 pandemic. “I didn’t understand how bad it was until I experienced it myself. It is indeed super ironic,” Orr explained.
This personal experience fueled her collaboration with researchers at the University of Calgary’s Hotchkiss Brain Institute and the Barrow Neurological Institute in Phoenix, Arizona, to review 26 studies spanning the last nine years. the goal was to update the 2016 guidelines established by the American Headache Society for managing migraine attacks in emergency settings.
The Science Behind Occipital Nerve Blocks
The research highlights the effectiveness of occipital nerve blocks,a procedure involving the injection of a local anesthetic and a corticosteroid near the greater occipital nerve at the base of the skull.”the occipital nerves bring in pain signals to the same area of the brain where pain signals from all over the head are coming in. By anesthetizing these nerves,patients get relief,” orr explained. The injection effectively disrupts pain signaling pathways, offering significant relief.
While intravenous prochlorperazine, a dopamine receptor blocker, is also recommended, its limited availability makes occipital nerve blocks a more readily accessible option for many emergency departments.
Moving Away From Opioids
The updated guidelines strongly advise against using opioids to treat headaches. Researchers cite the availability of more effective treatments and the potential for addiction as key reasons for this advice. While opioid prescriptions for migraines have decreased as the 2016 guidelines, they remain prevalent, highlighting the need for wider adoption of alternative therapies.
Implementing the New Guidance and Advocating for Change
Dr. Orr, who was the lead author of the 2016 guidelines, is actively working to encourage their implementation across Canada. she has reached out to the Canadian Headache Society and other medical professionals to promote the new recommendations.”They’re looking at it and are likely to endorse the things on it,” she stated.
Migraines are recognized as one of the most common neurological diseases globally, with a strong genetic component and potential triggers ranging from childhood trauma to weather conditions and altitude.
Patient Advocacy and real-World Impact
Sandra pick, an elementary school teacher from Edmonton, Alberta, has battled migraines for 15 years. After experiencing three emergency room visits in the past six weeks, she recently received an occipital nerve block. “It made a big difference in relieving her pain within 30 minutes,” Pick shared.The relief lasted approximately 24 hours, allowing her to rest and recover.
Pick now plans to advocate for the wider availability of this treatment, emphasizing the importance of patients actively seeking the care they need.”It’s kind of a sad part of the migraine where we kind of doubt ourselves… I think we really need to advocate for ourselves,” she saeid.
